Cancer Immunology – News and Features

Research shows that some lung cancer cells retain a “memory” of the healthy cell where they came from — one that might be exploited to make an emerging type of lung cancer treatment called KRAS inhibition more effective.

A new study has identified an antibody that can supercharge the immune system, helping to overcome a previously unknown mechanism by which cancer cells prevent phagocytosis.

A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.

Macrophages, a type of white blood cell that can destroy invading pathogens, have an innate ability to infiltrate tumor cells, making them a potentially important tool in treatments that use transplanted cells to fight disease, known as cell therapy.

Researchers have identified the genetic changes that occur during pancreatic cancer metastasis and have found a drug to disrupt the process.

Disrupting one gene in CAR T cells used for cancer therapy makes them more potent and able to fight the cancer for longer, reports a new study.

Cancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.

Researchers suggest that when used in a form that can be delivered directly into the tumor cell, polyinosine–polycytidylic acid (pIC) suppresses tumor growth, induces cancer cell death and enhances survival.

Mucosal-associated invariant T (MAIT) cells don't obey the usual immune cell rules, and new research has revealed another "superpower" of this cell type.